{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:48:04Z","timestamp":1768517284640,"version":"3.49.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,31]],"date-time":"2016-12-31T00:00:00Z","timestamp":1483142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.nrl.2014.10.009","type":"journal-article","created":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T01:03:13Z","timestamp":1418778193000},"page":"241-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Aspectos cl\u00ednicos, moleculares y farmacol\u00f3gicos en los trastornos asociados a gen 1 del retraso mental del X fr\u00e1gil"],"prefix":"10.1016","volume":"32","author":[{"given":"A.","family":"Pugin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Faundes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Santa Mar\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Curotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Aliaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Salas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.I.","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Alliende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrl.2014.10.009_bib0005","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/mrdd.10031","article-title":"The epidemiology of mental retardation: Challenges and opportunities in the new millennium","volume":"8","author":"Leonard","year":"2002","journal-title":"Ment Retard Dev Disabil Res Rev."},{"key":"10.1016\/j.nrl.2014.10.009_bib0010","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1136\/jmg.2008.059055","article-title":"The fragile X prevalence paradox","volume":"45","author":"Hagerman","year":"2008","journal-title":"J Med Genet."},{"key":"10.1016\/j.nrl.2014.10.009_bib0015","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/157339608783565770","article-title":"The fragile X family of disorders: A model for autism and targeted treatments","volume":"4","author":"Hagerman","year":"2008","journal-title":"Curr Pediatr Rev"},{"key":"10.1016\/j.nrl.2014.10.009_bib0020","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ajmg.10427","article-title":"Prevalence of the fragile X syndrome in African-Americans","volume":"110","author":"Crawford","year":"2002","journal-title":"Am J Med Genet."},{"key":"10.1016\/j.nrl.2014.10.009_bib0025","first-page":"1006","article-title":"Prevalence of carriers of premutation-size alleles of the FMRI gene and implications for the population genetics of the fragile X syndrome","volume":"57","author":"Rousseau","year":"1995","journal-title":"Am J Hum Genet."},{"key":"10.1016\/j.nrl.2014.10.009_bib0030","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/MOP.0b013e32834c7f1a","article-title":"Advances in understanding fragile X syndrome and related disorders","volume":"23","author":"Rooms","year":"2011","journal-title":"Curr Opin Pediatr."},{"key":"10.1016\/j.nrl.2014.10.009_bib0035","series-title":"Fragile X syndrome: Diagnosis, treatment and research. 3","first-page":"3","article-title":"Physical and behavioral phenotype","author":"Hagerman","year":"2002"},{"key":"10.1016\/j.nrl.2014.10.009_bib0040","series-title":"Fragile X Syndrome: Diagnosis, Treatment and Research. 3","first-page":"287","article-title":"Medical follow-up and pharmacotherapy","author":"Hagerman","year":"2002"},{"key":"10.1016\/j.nrl.2014.10.009_bib0045","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1542\/peds.93.6.992","article-title":"Do young boys with fragile X syndrome have macroorchidism?","volume":"93","author":"Lachiewicz","year":"1994","journal-title":"Pediatrics."},{"key":"10.1016\/j.nrl.2014.10.009_bib0050","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1365-2788.2006.00803.x","article-title":"Cognitive, language and social-cognitive skills of individuals with fragile X syndrome with and without autism","volume":"50","author":"Lewis","year":"2006","journal-title":"J Intellect Disabil Res."},{"key":"10.1016\/j.nrl.2014.10.009_bib0055","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/ajmg.a.30229","article-title":"Autism spectrum disorder in fragile X syndrome: Communication, social interaction, and specific behaviors","volume":"129A","author":"Kaufmann","year":"2004","journal-title":"Am J Med Genet."},{"key":"10.1016\/j.nrl.2014.10.009_bib0060","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00004703-200112000-00008","article-title":"The behavioral phenotype in fragile X: Symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders","volume":"22","author":"Rogers","year":"2001","journal-title":"J Dev Behav Pediatr."},{"key":"10.1016\/j.nrl.2014.10.009_bib0065","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ajmg.a.30353","article-title":"Mapping nonverbal IQ in young boys with fragile X syndrome","volume":"132","author":"Skinner","year":"2005","journal-title":"Am J Med Genet A."},{"key":"10.1016\/j.nrl.2014.10.009_bib0070","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mrdd.20006","article-title":"Phenotypic variation and FMRP levels in fragile X","volume":"10","author":"Loesch","year":"2004","journal-title":"Ment Retard Dev Disabil Res Rev."},{"key":"10.1016\/j.nrl.2014.10.009_bib0075","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1352\/0895-8017(2005)110<107:ASOBWF>2.0.CO;2","article-title":"Academic skills of boys with fragile X syndrome: Profiles and predictors","volume":"110","author":"Roberts","year":"2005","journal-title":"Am J Ment Retard."},{"key":"10.1016\/j.nrl.2014.10.009_bib0080","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.chc.2007.03.001","article-title":"Fragile X syndrome: Assessment and treatment implications","volume":"16","author":"Reiss","year":"2007","journal-title":"Child Adolesc Psychiatr Clin N Am."},{"key":"10.1016\/j.nrl.2014.10.009_bib0085","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1352\/1944-7558-115.6.461","article-title":"Seizure in fragile X syndrome: Characteristics and comorbid diagnoses","volume":"115","author":"Berry-Kravis","year":"2010","journal-title":"Am J Intellect DevDisabil"},{"key":"10.1016\/j.nrl.2014.10.009_bib0090","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1002\/ajmg.a.32290","article-title":"Secondary medical diagnosis in fragile X syndrome with and without autism spectrum disorder","volume":"146A","author":"Garcia-Nonell","year":"2008","journal-title":"Am J Med Genet A."},{"key":"10.1016\/j.nrl.2014.10.009_bib0095","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1002\/ajmg.a.31405","article-title":"Autism spectrum disorder in Fragile X syndrome: Differential contribution of adaptive socialization and social withdrawal","volume":"140A","author":"Budimirovic","year":"2006","journal-title":"Am J Med Genet A."},{"key":"10.1016\/j.nrl.2014.10.009_bib0100","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1002\/ajmg.a.32439","article-title":"Co-occurring conditions associated with FMR1 gene variations: Findings from a national parent survey","volume":"146A","author":"Bailey","year":"2008","journal-title":"Am J Med Genet A."},{"key":"10.1016\/j.nrl.2014.10.009_bib0105","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1352\/1944-7558-115.6.473","article-title":"Self-injurious behavior and fragile x syndrome: Findings from the national fragile x survey","volume":"115","author":"Symons","year":"2010","journal-title":"Am J Intellect Dev Disabil."},{"key":"10.1016\/j.nrl.2014.10.009_bib0110","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/01.DBP.0000267563.18952.c9","article-title":"The Prader-Willi phenotype of fragile X syndrome","volume":"28","author":"Norwicki","year":"2007","journal-title":"J Dev Behav Pediatr."},{"key":"10.1016\/j.nrl.2014.10.009_bib0115","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1469-1809.2011.00694.x","article-title":"Fragile X syndrome: The FMR1 CGG repeat distribution among world populations","volume":"76","author":"Peprah","year":"2012","journal-title":"Ann Hum Genet."},{"key":"10.1016\/j.nrl.2014.10.009_bib0120","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.252.5009.1097","article-title":"Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome","volume":"252","author":"Oberl\u00e9","year":"1991","journal-title":"Science."},{"key":"10.1016\/j.nrl.2014.10.009_bib0125","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/978-3-7091-0932-8_23","article-title":"Molecular and cellular aspects of mental retardation in the Fragile X syndrome: From gene mutation\/s to spine dysmorphogenesis","volume":"970","author":"De Rubeis","year":"2012","journal-title":"Adv Exp Med Biol."},{"key":"10.1016\/j.nrl.2014.10.009_bib0130","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000072846","article-title":"Expression of the FMR1 gene","volume":"100","author":"Tassone","year":"2003","journal-title":"Cytogenet Genome Res."},{"key":"10.1016\/j.nrl.2014.10.009_bib0135","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1126\/science.1245831","article-title":"Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome","volume":"343","author":"Colak","year":"2014","journal-title":"Science."},{"key":"10.1016\/j.nrl.2014.10.009_bib0140","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ng0193-31","article-title":"A point mutation in the FMR-1 gene associated with fragile X mental retardation","volume":"3","author":"De Boulle","year":"1993","journal-title":"Nat Genet."},{"key":"10.1016\/j.nrl.2014.10.009_bib0145","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/(SICI)1096-8628(20000313)91:2<144::AID-AJMG14>3.0.CO;2-V","article-title":"Clinical involvement and protein expression in individuals with the FMR1 premutation","volume":"91","author":"Tassone","year":"2000","journal-title":"Am J Med Genet."},{"key":"10.1016\/j.nrl.2014.10.009_bib0150","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/cge.12278","article-title":"FXTAS in an unmethylated mosaic male with fragile X syndrome from Chile","volume":"86","author":"Santa Mar\u00eda","year":"2014","journal-title":"Clin Genet."},{"key":"10.1016\/j.nrl.2014.10.009_bib0155","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00004583-200203000-00002","article-title":"Genetic and environmental influences on the cognitive outcomes of children with fragile X syndrome","volume":"41","author":"Dyer-Friedman","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.nrl.2014.10.009_bib0160","first-page":"1025","article-title":"Mental status of females with an FMR1 gene full mutation","volume":"58","author":"De Vries","year":"1996","journal-title":"Am J Hum Genet."},{"key":"10.1016\/j.nrl.2014.10.009_bib0170","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/j.neuropsychologia.2004.05.002","article-title":"A neuropsychological investigation of male premutation carriers of fragile X syndrome","volume":"42","author":"Moore","year":"2004","journal-title":"Neuropsychologia."},{"key":"10.1016\/j.nrl.2014.10.009_bib0175","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1086\/302720","article-title":"Elevated levels of FMR1 mRNA in carrier males: A new mechanism of involvement in the fragile-X syndrome","volume":"66","author":"Tassone","year":"2000","journal-title":"Am J Hum Genet."},{"key":"10.1016\/j.nrl.2014.10.009_bib0180","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jama.291.4.460","article-title":"Penetrance of the fragile X-associated tremor\/ataxia syndrome in a premutation carrier population","volume":"291","author":"Jacquemont","year":"2004","journal-title":"JAMA."},{"key":"10.1016\/j.nrl.2014.10.009_bib0185","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1212\/WNL.0b013e3181f73660","article-title":"Motor and mental dysfunction in mother-daughter transmitted FXTAS","volume":"75","author":"Rodriguez-Revenga","year":"2010","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2014.10.009_bib0190","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S1474-4422(13)70125-X","article-title":"Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor\/ataxia syndrome","volume":"12","author":"Hagerman","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nrl.2014.10.009_bib0195","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1212\/01.WNL.0000148723.37489.3F","article-title":"FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia","volume":"64","author":"Brussino","year":"2005","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2014.10.009_bib0200","unstructured":"GeneReviews [Internet]. Seattle: University of Washington; 1993-2014. FMR1-Related disorders; 2012 Abril 26 [citado 6 Oct 2014]. Disponible en: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1384\/"},{"key":"10.1016\/j.nrl.2014.10.009_bib0205","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/gim.2012.34","article-title":"AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome","volume":"14","author":"Yrigollen","year":"2012","journal-title":"Genet Med."},{"key":"10.1016\/j.nrl.2014.10.009_bib0210","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/00125817-200105000-00010","volume":"3","author":"Maddalena","year":"2001","journal-title":"Genet Med."},{"key":"10.1016\/j.nrl.2014.10.009_bib0215","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10897-007-9099-y","article-title":"Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders","volume":"16","author":"McConkie-Rosell","year":"2007","journal-title":"J Genet Couns."},{"key":"10.1016\/j.nrl.2014.10.009_bib0220","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/CIA.S1794","article-title":"Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems","volume":"3","author":"Hagerman","year":"2008","journal-title":"Clin Interv Aging."},{"key":"10.1016\/j.nrl.2014.10.009_bib0225","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4161\/epi.27473","article-title":"Non-coding RNAs as direct and indirect modulators of epigenetic regulation","volume":"9","author":"Peschansky","year":"2014","journal-title":"Epigenetics."},{"key":"10.1016\/j.nrl.2014.10.009_bib0230","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fnmol.2013.00053","article-title":"Long non-coding RNAs in neurodevelopmental disorders","volume":"6","author":"Van Devondervoort","year":"2013","journal-title":"Front Mol Neurosci."},{"key":"10.1016\/j.nrl.2014.10.009_bib0235","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0092-8674(93)90420-U","article-title":"The protein product of the fragile X gene, FMR1, has characteristics of an RNA binding protein","volume":"74","author":"Siomi","year":"1993","journal-title":"Cell."},{"key":"10.1016\/j.nrl.2014.10.009_bib0240","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.neuroscience.2014.05.006","article-title":"Distribution of fragile X mental retardation protein in the human auditory brainstem","volume":"273","author":"Beebe","year":"2014","journal-title":"Neuroscience."},{"key":"10.1016\/j.nrl.2014.10.009_bib0245","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.drudis.2014.01.013","article-title":"Fragile X syndrome neurobiology translates into rational therapy","volume":"19","author":"Braat","year":"2014","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.nrl.2014.10.009_bib9245","unstructured":"Maurin T, Zongaro S, Bardoni B. Fragile X Syndrome From molecular pathology to therapy. Neurosci Biobehav Rev. En prensa."},{"key":"10.1016\/j.nrl.2014.10.009_bib0255","doi-asserted-by":"publisher","unstructured":"Chen E, Sharma MR, Shi X, Agrawal RK, Joseph S. Fragile X Mental Retardation Protein Regulates Translation by Binding Directly to the Ribosome. Mol Cell. 2014;54:407-17.","DOI":"10.1016\/j.molcel.2014.03.023"},{"key":"10.1016\/j.nrl.2014.10.009_bib0260","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.pediatrneurol.2013.12.001","article-title":"Mechanism-based treatments in neurodevelopmental disorders: Fragile X syndrome","volume":"50","author":"Berry-Kravis","year":"2014","journal-title":"Pediatr Neurol."},{"key":"10.1016\/j.nrl.2014.10.009_bib0265","doi-asserted-by":"publisher","first-page":"18234","DOI":"10.1523\/JNEUROSCI.2207-13.2013","article-title":"The Fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses","volume":"33","author":"Janusz","year":"2013","journal-title":"J Neurosci."},{"key":"10.1016\/j.nrl.2014.10.009_bib0270","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.nbd.2014.01.008","article-title":"GABAergic circuit dysfunction in the Drosophila Fragile X syndrome model","volume":"65","author":"Gatto","year":"2014","journal-title":"Neurobiol Dis."},{"key":"10.1016\/j.nrl.2014.10.009_bib0275","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/mrdd.20010","article-title":"The fragile X syndrome: From molecular genetics to neurobiology","volume":"10","author":"Willemsen","year":"2004","journal-title":"Ment Retard Dev Disabil Res Rev."},{"key":"10.1016\/j.nrl.2014.10.009_bib0280","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.devcel.2008.04.003","article-title":"A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome","volume":"14","author":"Dictenberg","year":"2008","journal-title":"Dev Cell."},{"key":"10.1016\/j.nrl.2014.10.009_bib0285","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0092-8674(03)00079-5","article-title":"The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses","volume":"112","author":"Zalfa","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.nrl.2014.10.009_bib0290","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.mcn.2009.09.013","article-title":"Fragile X mental retardation protein control of neuronal mRNA metabolism: Insights into mRNA stability","volume":"43","author":"De Rubeis","year":"2010","journal-title":"Mol Cell Neurosci."},{"key":"10.1016\/j.nrl.2014.10.009_bib0295","doi-asserted-by":"publisher","first-page":"15964","DOI":"10.1523\/JNEUROSCI.0202-13.2013","article-title":"Activation of synaptic group II metabotropic glutamate receptors induces long-term depression at GABAergic synapses in CNS neurons","volume":"33","author":"Tang","year":"2013","journal-title":"Neurosci."},{"key":"10.1016\/j.nrl.2014.10.009_bib0300","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nm.3127","article-title":"Targeting the endocannabinoid system in the treatment of fragile X syndrome","volume":"19","author":"Busquets-Garcia","year":"2013","journal-title":"Nat Med."},{"key":"10.1016\/j.nrl.2014.10.009_bib0305","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.neuron.2008.10.004","article-title":"Fragile X syndrome: Loss of local mRNA regulation alters synaptic development and function","volume":"60","author":"Bassell","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.nrl.2014.10.009_bib0310","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.tins.2004.04.009","article-title":"The mGluR theory of fragile X mental retardation","volume":"27","author":"Bear","year":"2004","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.nrl.2014.10.009_bib0315","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/cercor\/10.10.1038","article-title":"Dendritic spine structural anomalies in fragile-X mental retardation syndrome","volume":"10","author":"Irwin","year":"2000","journal-title":"Cereb Cortex."},{"key":"10.1016\/j.nrl.2014.10.009_bib0320","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1471-4159.2006.03701.x","article-title":"MMP-7 disrupts dendritic spines in hippocampal neurons through NMDA receptor activation","volume":"97","author":"Bilousova","year":"2006","journal-title":"J Neurochem."},{"key":"10.1016\/j.nrl.2014.10.009_bib0325","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.tins.2007.06.003","article-title":"The GABAA receptor: A novel target for treatment of fragile X?","volume":"30","author":"D\u2019Hulst","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.nrl.2014.10.009_bib0330","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jgg.2014.08.003","article-title":"Towards Understanding RNA-Mediated Neurological Disorders","volume":"41","author":"Duan","year":"2014","journal-title":"J Genet Genomics."},{"key":"10.1016\/j.nrl.2014.10.009_bib0335","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.neuron.2007.07.021","article-title":"RNA-binding proteins hnRNP A2\/B1 and CUGBP1 suppress fragile X CGG premutation repeatinduced neurodegeneration in a Drosophila model of FXTAS","volume":"55","author":"Sofola","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.nrl.2014.10.009_bib0340","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2217\/fnl.09.44","article-title":"Evidence for RNA-mediated toxicity in the fragile X-associated tremor\/ataxia syndrome","volume":"1","author":"Galloway","year":"2009","journal-title":"Future Neurol."},{"key":"10.1016\/j.nrl.2014.10.009_bib0345","first-page":"545","article-title":"Mitochondrial dysfunction in fragile X-associated tremor\/ataxia syndrome","volume":"429","author":"Ross-Inta","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nrl.2014.10.009_bib0350","doi-asserted-by":"publisher","first-page":"e1486","DOI":"10.1371\/journal.pone.0001486","article-title":"A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome","volume":"3","author":"Khalil","year":"2008","journal-title":"PLoS One."},{"key":"10.1016\/j.nrl.2014.10.009_bib0355","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2353\/jmoldx.2008.070073","article-title":"A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations","volume":"10","author":"Tassone","year":"2008","journal-title":"J Mol Diagn."},{"key":"10.1016\/j.nrl.2014.10.009_bib0360","first-page":"1435","article-title":"Direct molecular analysis of FMR-1 gene mutation in patients with fragile Xq syndrome and their families","volume":"126","author":"Alliende","year":"1998","journal-title":"Rev Med Chil."},{"key":"10.1016\/j.nrl.2014.10.009_bib0365","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1525-1578(10)60594-6","article-title":"An enhanced polymerase chain reaction assay to detect pre- and full mutation alleles of the fragile X mental retardation 1 gene","volume":"7","author":"Saluto","year":"2005","journal-title":"J Mol Diagn."},{"key":"10.1016\/j.nrl.2014.10.009_bib0370","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1373\/clinchem.2009.136101","article-title":"A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome","volume":"56","author":"Filipovic-Sadic","year":"2010","journal-title":"Clin Chem."},{"key":"10.1016\/j.nrl.2014.10.009_bib0375","first-page":"34","article-title":"Clinical screening and FMR1 gene mutation analysis in male patients with Fragile X s\u00edndrome","volume":"77","author":"Alliende","year":"2006","journal-title":"Rev Chil Pediatr."},{"key":"10.1016\/j.nrl.2014.10.009_bib0380","doi-asserted-by":"publisher","unstructured":"Inaba Y, Schwartz CE, Bui QM, Li X, Skinner C, Field M, et al. Early Detection of Fragile X Syndrome: Applications of a Novel Approach for Improved Quantitative Methylation Analysis in Venous Blood and Newborn Blood Spots. Clin Chem. 2014;60:963-73.","DOI":"10.1373\/clinchem.2013.217331"},{"key":"10.1016\/j.nrl.2014.10.009_bib0385","doi-asserted-by":"publisher","first-page":"11557","DOI":"10.1073\/pnas.0504984102","article-title":"Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome","volume":"102","author":"Restivo","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nrl.2014.10.009_bib0390","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/mrdd.20007","article-title":"Psychopharmacology in fragile X syndrome: Present and future","volume":"10","author":"Berry-Kravis","year":"2004","journal-title":"Ment Retard Dev Disabil Res Rev."},{"key":"10.1016\/j.nrl.2014.10.009_bib0395","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.nurt.2010.04.001","article-title":"Aripiprazole in autism spectrum disorders and fragile X syndrome","volume":"7","author":"Erickson","year":"2010","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.nrl.2014.10.009_bib0400","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1542\/peds.2008-0317","article-title":"Advances in the treatment of fragile X syndrome","volume":"123","author":"Hagerman","year":"2009","journal-title":"Pediatrics."},{"key":"10.1016\/j.nrl.2014.10.009_bib0405","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ajmg.a.32268","article-title":"A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys","volume":"146","author":"Torrioli","year":"2008","journal-title":"Am J Med Genet A."},{"key":"10.1016\/j.nrl.2014.10.009_bib0410","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11689-010-9067-y","article-title":"Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: Prevalence and characterization","volume":"3","author":"Cordeiro","year":"2011","journal-title":"J Neurodev Disord."},{"key":"10.1016\/j.nrl.2014.10.009_bib0420","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/j.1469-8749.2002.tb00277.x","article-title":"Epilepsy in fragile X syndrome","volume":"44","author":"Berry-Kravis","year":"2002","journal-title":"Dev Med Child Neurol."},{"key":"10.1016\/j.nrl.2014.10.009_bib0425","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.bbr.2012.01.031","article-title":"Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model","volume":"229","author":"Heulens","year":"2012","journal-title":"Behav Brain Res."},{"key":"10.1016\/j.nrl.2014.10.009_bib0430","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.nurt.2006.11.003","article-title":"Ganaxolone","volume":"4","author":"Nohria","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nrl.2014.10.009_bib0435","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.molmed.2010.08.005","article-title":"Potential therapeutic interventions for fragile X syndrome","volume":"16","author":"Levenga","year":"2010","journal-title":"Trends Mol Med."},{"key":"10.1016\/j.nrl.2014.10.009_bib0440","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1124\/mol.109.056127","article-title":"Increased GABA (B) receptor mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures","volume":"76","author":"Pacey","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.nrl.2014.10.009_bib0445","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/2040-2392-1-12","article-title":"Fragile X and autism: Intertwined at the molecular level leading to targeted treatments","volume":"1","author":"Hagerman","year":"2010","journal-title":"Mol Autism."},{"key":"10.1016\/j.nrl.2014.10.009_bib0450","doi-asserted-by":"publisher","first-page":"152ra127","DOI":"10.1126\/scitranslmed.3004214","article-title":"Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial","volume":"4","author":"Berry-Kravis","year":"2012","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.nrl.2014.10.009_bib0455","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/jmg.2008.063701","article-title":"A pilot open label, single dose trial of fenobam in adults with fragile X syndrome","volume":"46","author":"Berry-Kravis","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.nrl.2014.10.009_bib0460","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1124\/jpet.111.185660","article-title":"CTEP: A novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor","volume":"339","author":"Lindemann","year":"2011","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.nrl.2014.10.009_bib0465","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/DBP.0b013e31817dc447","article-title":"Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome","volume":"29","author":"Berry-Kravis","year":"2008","journal-title":"J Dev Behav Pediatr."},{"key":"10.1016\/j.nrl.2014.10.009_bib0470","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/jmg.2008.061796","article-title":"Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model","volume":"46","author":"Bilousova","year":"2009","journal-title":"J Med Genet."},{"key":"10.1016\/j.nrl.2014.10.009_bib0475","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-2377-10-91","article-title":"Open-label add-on treatment trial of minocycline in fragile X syndrome","volume":"10","author":"Paribello","year":"2010","journal-title":"BMC Neurol."},{"key":"10.1016\/j.nrl.2014.10.009_bib0480","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/ddrr.78","article-title":"Treatments for fragile X syndrome: A closer look at the data","volume":"15","author":"Hall","year":"2009","journal-title":"Dev Disabil Res Rev."},{"key":"10.1016\/j.nrl.2014.10.009_bib0485","doi-asserted-by":"publisher","first-page":"852","DOI":"10.4088\/JCP.08r04476","article-title":"A review of fragile X premutation disorders: Expanding the psychiatric perspective","volume":"70","author":"Bourgeois","year":"2009","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.nrl.2014.10.009_bib0490","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/mds.21001","article-title":"Symptomatic treatment in the fragile X-associated tremor\/ataxia syndrome","volume":"21","author":"Hall","year":"2006","journal-title":"Mov Disord."},{"key":"10.1016\/j.nrl.2014.10.009_bib0495","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00401-011-0860-9","article-title":"Widespread non-central nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor\/ataxia syndrome and CGG knock-in mice","volume":"122","author":"Hunsaker","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nrl.2014.10.009_bib0500","doi-asserted-by":"publisher","unstructured":"Yang JC, Niu YQ, Simon C, Seritan AL, Chen L, Schneider A, et al. Memantine Effects on Verbal Memory in Fragile X-associated Tremor\/Ataxia Syndrome (FXTAS): a Double-Blind Brain Potential Study. Neuropsychopharmacology. 2014;39:2760-8.","DOI":"10.1038\/npp.2014.122"},{"key":"10.1016\/j.nrl.2014.10.009_bib0505","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10897-005-4802-x","article-title":"Genetic counseling for fragile X syndrome: Updated recommendations of the National Society of Genetic Counselors","volume":"14","author":"McConkie-Rosell","year":"2005","journal-title":"J Genet Couns."},{"key":"10.1016\/j.nrl.2014.10.009_bib0510","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.medcli.2013.05.025","article-title":"Clinical guideline of gene FMR1-associated diseases: Fragile X syndrome, primary ovarian insufficiency and tremor-ataxia syndrome","volume":"142","author":"Mil\u00e1","year":"2014","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.nrl.2014.10.009_bib0515","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/1097-0223(200008)20:8<611::AID-PD881>3.0.CO;2-M","article-title":"Screening for fragile X syndrome in women of reproductive age","volume":"20","author":"Pesso","year":"2000","journal-title":"Prenat Diagn."},{"key":"10.1016\/j.nrl.2014.10.009_bib0520","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1001\/jamaneurol.2013.4808","article-title":"Newborn screening for fragile X syndrome","volume":"71","author":"Tassone","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nrl.2014.10.009_bib0525","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.yapd.2009.08.008","article-title":"Fragile X: A family of disorders","volume":"56","author":"Chonchaiya","year":"2009","journal-title":"Adv Pediatr."}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485314002321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485314002321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T13:45:36Z","timestamp":1650807936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485314002321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0213485314002321"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2014.10.009","relation":{},"ISSN":["0213-4853"],"issn-type":[{"value":"0213-4853","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspectos cl\u00ednicos, moleculares y farmacol\u00f3gicos en los trastornos asociados a gen 1 del retraso mental del X fr\u00e1gil","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2014.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}